Oligonucleotide drug development is on a steady increase as more therapies are being discovered. CMIC has experience supporting hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis. Our experience includes decoy, antisense, siRNA and aptamer.
Since 2012, CMIC has supported hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis for oligonucleotide-based drugs, in various tissues, urine and plasma for preclinical and clinical studies.
- Partnered with recognized global leaders in RNA-targeted discoveries
- Nearly 100 individual compounds successfully validated since 2012
- Vast experience with chemically modified oligonucleotides including GalNAc conjugate, cholesterol conjugate, thymidylic acid and phosphate
| Experience | Platforms | Capabilities | Biomatrix |
| Decoy Antisense siRNA Aptamer |
HPLC-UV, Hybridization, LC-MS/MS, HPLC-FD, LC-HRMS, qPCR, ECL |
Method transfer, development & qualification, validation, Quantitative bioanalysis, Metabolite ID & confirmation | Plasma/Serum, Blood, Urine, CSF, Muscle, Liver, Kidney, Lung, Brain, Heart, Tumor Tissue, PBMC, Ocular |
